Atalaya Capital Management’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Atalaya Capital Management’s Portfolio FLACW Stock Details FLACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,333	Closed	-$1K	–	399
2022 Q1	$1K	Hold	3,333	–	–	﹤0.01%	408
2021 Q4	$2K	Hold	3,333	–	–	﹤0.01%	415
2021 Q3	$2K	Hold	3,333	–	–	﹤0.01%	354
2021 Q2	$4K	Hold	3,333	–	–	﹤0.01%	332
2021 Q1	$3K	Buy	+3,333	New	+$5.64K	﹤0.01%	266

Other funds holding FLACW

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32M AUM 108.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Atalaya Capital Management's FLACW Position: Q2 2022 in Review

Atalaya Capital Management sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q2 2022, closing a stake of 3,333 shares — an estimated $1K sold.

Atalaya Capital Management first reported a position in FLACW in Q1 2021 and held it in 5 quarters. The position peaked at $4K in Q2 2021. 30 funds tracked by Wall St. Rank hold FLACW as of Q2 2022.

Atalaya Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q2 2022 after selling out during the quarter.
Atalaya Capital Management sold 3,333 Frazier Lifesciences Acquisition Corporation Warrant shares in Q2 2022, an estimated $1K.
Atalaya Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q1 2021 and held it in 5 quarters.
Atalaya Capital Management's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $4K in Q2 2021.
30 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q2 2022.

Based on Atalaya Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.